
Daphne Koller - The Future of AI in Biology and Drug Discovery
Daphne Koller wrote the book that many of us learned probabilistic graphical models from, founded Coursera, and now runs insitro, which is trying to make drug discovery a machine-learning problem. We start with the bitter lesson. She agrees with most of it and then says where it stops working: biology doesn't have enough data, structure is how people understand anything, and making a drug is a question about an intervention that hasn't happened yet, not a pattern in data you already have. Most of the episode is about why drug discovery is hard. Ninety percent of drugs that reach the clinic fail, and mostly not because the molecule was bad. The molecule usually does what it was designed to do. It just turns out the thing it was designed to do had nothing to do with the disease. Only 22% of diseases have any approved drug at all, and she calls that an upper bound on what we understand, not a lower bound. She also gets into what agents are and aren't good for in a wet lab, why cells don't grow faster no matter how many GPUs you point at them, what it would take to have real foundation models for biology, and why almost all of biology is still out of distribution. Plus GLP-1s and what human data keeps teaching us, whether AI can make the kind of leap that turned a bacterial immune system into CRISPR, and what she'd build if she were starting Coursera today. Key Topics The impact of scaling and data in machine learning The importance of structure and causality in AI Challenges in drug discovery and biological understanding The role of foundation models in biology Ethical considerations in AI and biomedical research Chapters 00:00 Introduction to Machine Learning and Drug Discovery 02:00 The Bitter Lesson and Its Implications 06:48 Challenges in Drug Design and Discovery 11:48 Ethical Considerations in Human Research 17:20 The Drug Discovery Pipeline Explained 29:30 Integrating AI in Experimental Design 35:38 The Role of Human Judgment in Drug Design 37:14 Future of Drug Design: Efficiency vs. Automation 39:37 Challenges in AI and Data Availability for Biology 41:08 Foundation Models: Potential and Limitations 43:39 Causality in Biological Data: Importance and Challenges 45:18 Creativity vs. Understanding in Drug Design 48:17 Balancing Investments in Data, Algorithms, and Experiments 50:07 The Value of Simulations in Drug Discovery 52:03 Mathematical Frameworks in Biology: Utility and Limitations 54:14 The Future of Drug Discovery: Optimism and Innovations 56:28 The Impact of Coursera on Education 01:00:33 The Role of Universities in Lifelong Learning 01:04:06 Connecting Dots: The Fun of Variety in Work 01:05:46 Optimism for the Future of Drug Discovery Music "Kid Kodi" - Blue Dot Sessions - via Free Music Archive - CC BY-NC 4.0.
- Transcript










